Du Xiaoli, Tao Qianqian, Du Hongxia, Zhao Zhenbang, Dong Yu, He Shuang, Shao Rui, Wang Yule, Han Wenrun, Wang Xintong, Zhu Yan
Institute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Department of pharmacy, Inner Mongolia Medical College, Hohhot, China.
Front Pharmacol. 2021 May 18;12:638298. doi: 10.3389/fphar.2021.638298. eCollection 2021.
Hypertension-induced renal damage is a serious and complex condition that has not been effectively treated by conventional blood pressure-lowering drugs. Tengdan capsule (TDC) is a China FDA-approved compound herbal medicine for treating hypertension; however, its chemical basis and pharmacological efficacy have not been fully investigated in a preclinical setting. High-performance liquid chromatography (HPLC) was used to identify and quantify the major chemical components of TDC extracted from ultrapure water. Adult spontaneously hypertensive rats (SHR) and age/sex-matched Wistar Kyoto normotensive rats (WKY) were both treated with TDC, losartan, or saline for one month, and their blood pressure (BP) was monitored at the same time by tail-cuff BP system. Biochemical indexes such as urine creatinine (CRE) and blood urea nitrogen (BUN) were determined. Kidney tissue sections were examined with (H&E), and Masson staining to evaluate the pathological effect of TDC on SHR's kidneys. After TDC treatment, the differentially expressed proteins in the kidneys of SHR were identified by the TMT-based quantitative proteomics analysis, which may provide the targets and possible mechanisms of TDC action. In addition, Western blot analysis, RT-qPCR, and ELISA assays were carried out to further verify the proteomics findings. Finally, two different models involving renal injuries were established using human kidney HEK293 cells; and the molecular mechanism of TDC kidney protection was demonstrated. Seven chemical compounds, namely Notoginsenoside R1, Ginsenoside RG1, Ginsenoside Re, Ginsenoside Rb1, Sodium Danshensu, Protocatechualdehyde, and Salvianolic acid B, were identified and quantified from the water-soluble extracts of TDC by HPLC. study using rats showed that TDC effectively reduced BP, BUN, and CRE levels and attenuated renal fibrosis in SHR, and ameliorated damage to the kidneys. Proteomics and subsequent bioinformatics analyses indicated that periostin-mediated inflammatory response and TGFβ/Smad signaling pathway proteins were closely related to the therapeutic effect of TDC in rat kidneys. Western blot analysis and RT-qPCR showed that TDC markedly downregulated the mRNA and protein expression of periostin in renal tissues compared to the untreated SHR. In addition, TGF-β and COL1A1 mRNA levels also decreased in SHR renal tissues following TDC treatment. studies showed that low to medium doses of TDC down-regulated the expression of periostin in the injury model of HEK293 cell. In addition, medium to high doses of TDC significantly inhibited collagen deposition in TGFβ1-induced HEK293 cell fibrosis. Major components from the compound herbal medicine Tengdan Capsule are identified and quantified. TDC effectively lowers blood pressure and protects against renal damage caused by hypertension in SHR. Mechanistically, TDC blocks periostin by regulating the TGF-β/Smad signaling pathway in the kidney, both and . Preventing periostin-mediated renal fibrosis and inflammation might be a promising strategy for treating a hypertensive renal injury.
高血压所致肾损害是一种严重且复杂的病症,传统降压药物尚未对其进行有效治疗。藤丹胶囊(TDC)是一种经中国食品药品监督管理总局批准用于治疗高血压的复方草药制剂;然而,其化学基础和药理功效在临床前研究中尚未得到充分探究。采用高效液相色谱法(HPLC)对从超纯水中提取的TDC的主要化学成分进行鉴定和定量分析。将成年自发性高血压大鼠(SHR)和年龄/性别匹配的Wistar Kyoto正常血压大鼠(WKY)均用TDC、氯沙坦或生理盐水治疗1个月,同时通过尾套血压系统监测其血压(BP)。测定尿肌酐(CRE)和血尿素氮(BUN)等生化指标。用苏木精-伊红(H&E)染色和Masson染色检查肾组织切片,以评估TDC对SHR肾脏的病理作用。TDC治疗后,通过基于串联质谱标签(TMT)的定量蛋白质组学分析鉴定SHR肾脏中差异表达的蛋白质,这可能为TDC的作用靶点和可能机制提供依据。此外,进行蛋白质免疫印迹分析、逆转录-定量聚合酶链反应(RT-qPCR)和酶联免疫吸附测定(ELISA)试验以进一步验证蛋白质组学研究结果。最后,利用人肾HEK293细胞建立了两种不同的肾损伤模型;并阐明了TDC肾脏保护的分子机制。通过HPLC从TDC的水溶性提取物中鉴定并定量了7种化合物,即三七皂苷R1、人参皂苷RG1、人参皂苷Re、人参皂苷Rb1、丹参素钠、原儿茶醛和丹酚酸B。对大鼠的研究表明,TDC可有效降低SHR的血压、BUN和CRE水平,减轻肾纤维化,并改善肾脏损伤。蛋白质组学及后续生物信息学分析表明,骨膜蛋白介导的炎症反应和转化生长因子β(TGFβ)/Smad信号通路蛋白与TDC对大鼠肾脏的治疗作用密切相关。蛋白质免疫印迹分析和RT-qPCR显示,与未治疗的SHR相比,TDC显著下调肾组织中骨膜蛋白的mRNA和蛋白表达。此外,TDC治疗后SHR肾组织中TGF-β和Ⅰ型胶原蛋白α1(COL1A1)的mRNA水平也降低。研究表明,低至中剂量的TDC可下调HEK293细胞损伤模型中骨膜蛋白的表达。此外,中至高剂量的TDC可显著抑制TGFβ1诱导的HEK293细胞纤维化中的胶原沉积。鉴定并定量了复方草药制剂藤丹胶囊的主要成分。TDC可有效降低血压,并保护SHR免受高血压所致的肾损害。从机制上讲,TDC通过调节肾脏中的TGF-β/Smad信号通路来阻断骨膜蛋白,二者兼具。预防骨膜蛋白介导的肾纤维化和炎症可能是治疗高血压肾损伤的一种有前景的策略。